12 results
10-K
2020 FY
TSHA
Taysha Gene Therapies Inc
3 Mar 21
Annual report
9:00am
the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to conduct ongoing
10-K
2020 FY
EX-10.15
TSHA
Taysha Gene Therapies Inc
3 Mar 21
Annual report
9:00am
, storage, laboratory, supply chain, production, testing, quality control, manufacturing, general office, kitchen, amenity uses and uses ancillary
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
17 Dec 20
Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility
4:16pm
supply chain, which aligns well with our strategic goals. We are excited to expand our footprint in North Carolina, home to a thriving gene therapy … the potential demand of our robust portfolio, establishing internal capacity using our HEK293 suspension process is a key addition to our manufacturing supply
10-Q
vdoau88u5
12 Nov 20
Quarterly report
4:27pm
424B4
osm8 i6u1i61d1ty5
25 Sep 20
Prospectus supplement with pricing info
12:00am
S-1/A
2jpn40riie
8 Sep 20
IPO registration (amended)
4:43pm
S-1
ftswjikoqvccey2kve
2 Sep 20
IPO registration
5:02pm
DRS
zekxo somzb561kr7
3 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next